Enanta Pharmaceuticals | ENTA - Cash And Equivalent


Enanta Pharmaceuticals reported $37.44M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Anika Therapeutics USD 38.41M 2.61M Jun/2026
Arrowhead Research USD 19.68M 127.85M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Immunic USD 186.63M 171.15M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Insmed USD 544.76M 37.42M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Ligand Pharmaceuticals USD 1.01B 891.62M Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Novavax USD 191.46M 36.9M Jun/2026
Pfizer USD 976M 727M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026